RT Journal Article
T1 Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients.
A1 Vegas-Revenga, Nuria
A1 Martin-Varillas, Jose Luis
A1 Calvo-Rio, Vanesa
A1 Gonzalez-Mazon, Iñigo
A1 Sanchez-Bilbao, Lara
A1 Beltran, Emma
A1 Fonollosa, Alejandro
A1 Maiz, Olga
A1 Blanco, Ana
A1 Cordero-Coma, Miguel
A1 Ortego, Norberto
A1 Torre, Ignacio
A1 Francisco Hernandez, Felix
A1 Muñoz-Fernandez, Santiago
A1 Esteban Ortega, Maria Mar
A1 Diaz-Llopis, Manuel
A1 Cañal, Joaquin
A1 Ventosa, Juan Antonio
A1 Demetrio-Pablo, Rosalia
A1 Agudo-Bilbao, Mario
A1 Dominguez-Casas, Lucia
A1 Hernandez, Jose Luis
A1 Castañeda, Santos
A1 Gonzalez-Gay, Miguel A
A1 Blanco, Ricardo
AB Rapid control of intraocular inflammation in non-infectious uveitis (NIU) is mandatory to avoid irreversible structural and functional damage. In this study, we assessed the efficacy and safety of intravenous methylprednisolone (IVMP) pulses in the treatment of NIU. A retrospective case series of 112 patients who received IVMP for the treatment of NIU, either isolated or associated with different underlying diseases, was studied. Intraocular inflammation (anterior chamber cells and vitritis) was the primary outcome measure. Secondary outcome measures were macular thickness and best corrected visual acuity (BCVA). Patients were assessed at baseline visit, and at days 2-5, 7, 15 and 30 after initiation of IVMP pulse therapy. A total of 112 patients (mean age 42±14.5 yrs) were assessed. An underlying immune-mediated disease was diagnosed in 73 patients. Inflammatory ocular patterns were panuveitis (n=68), posterior uveitis (n=30), anterior uveitis (AU) (n=12), and intermediate uveitis (n=2). Additionally, patients presented cystoid macular oedema (CME) (n=50), retinal vasculitis (n=37), and exudative retinal detachment (n=31). Therapies used before IVMP included intraocular glucocorticoids (n=4), high-dose oral systemic glucocorticoids (n=77), and conventional (n=107) or biologic (n=40) immunosuppressive drugs. IVMP dose ranged from 80 to 1,000 mg/day for 3-5 consecutive days. Improvement was observed in AU, vitritis, BCVA, CME, and retinal vasculitis. At first month evaluation, total remission was achieved in 19 patients. Side effects of IVMP were respiratory infections (n=3), uncontrolled hyperglycaemia (n=1), herpes zoster (n=1), and oral candidiasis (n=1). IVMP pulse therapy was effective and safe, and achieved rapid control of NIU.
PB Clinical and Experimental Rheumatology
SN 0392-856X
YR 2021
FD 2021-02-08
LK http://hdl.handle.net/10668/21838
UL http://hdl.handle.net/10668/21838
LA en
NO Vegas-Revenga N, Martín-Varillas JL, Calvo-Río V, González-Mazón I, Sánchez-Bilbao L, Beltrán E, et al.  Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. Clin Exp Rheumatol. 2022 Jan;40(1):142-149.
NO The study was partially supported by RETICS Programs, RD08/0075 (RIER) and RD12/0009/0013 from Instituto de Salud Carlos III (ISCIII) (Spain)
DS RISalud
RD Apr 10, 2025